Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cipla Forms Joint Venture Company With Chinese Firm For Biosimilars Foray

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's top generic drug maker, Cipla, is speeding up its entry into biosimilars with the newly named Biomab, an equal stake joint venture with an undisclosed Chinese company

You may also be interested in...

Made In China, Sold In India: Cipla’s First Splash In Biosimilars Is A Cut Price Version Of Enbrel

The homegrown Indian drug manufacturer will sell its drug 30% cheaper than Amgen’s product and aims to capture significant share of the market.

Biosimilar Prices May Fall Dramatically With More Than 50 Companies Looking For Market Share

India's Cipla Unwraps Its Biosimilars Ambitions With A Presence In India And Shanghai; Earmarks $65 Million In First Push

MUMBAI - Many months after keeping its biosimilars plans under wraps, Cipla - India's second-largest drug maker - shared some parts of its proposed big picture that revolves around a manufacturing site in Goa, India, and another firm in Hong Kong that is putting up a biologics manufacturing facility in Shanghai

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts